Corcept Therapeutics Soars as FDA Greenlights Relacorilant for Hard‑to‑Treat Ovarian Cancer
Corcept Therapeutics Inc. (NASDAQ: CORT) stock is surging after the FDA approved its cancer drug relacorilant in combination with nab‑paclitaxel for adults with platinum‑resistant ovarian cancer, including epithelial ovarian, fallopian tube, and primary peritoneal cancer. This landmark FDA approval transforms relacorilant from a high‑risk pipeline asset into a commercial oncology drug and positions Corcept as a more diversified endocrine‑oncology company.
FDA approval of relacorilant for ovarian cancer
The FDA approved relacorilant, an oral selective glucocorticoid receptor antagonist, plus nab‑paclitaxel as a new treatment for patients with platinum‑resistant ovarian cancer who have already received multiple lines of therapy. The approval is based on positive Phase 3 data showing that relacorilant plus nab‑paclitaxel improved overall survival and progression‑free survival compared with chemotherapy alone in this hard‑to‑treat ovarian cancer population.
Why Corcept Therapeutics stock is rising
Corcept Therapeutics stock is rallying because this FDA cancer drug approval validates relacorilant’s mechanism in oncology and adds a new growth driver alongside Korlym in Cushing’s syndrome. After prior regulatory setbacks, including an FDA rejection in hypercortisolism, investors are now re‑rating CORT as a cancer drug developer with a de‑risked, late‑stage asset in ovarian cancer.
Investor outlook for CORT and relacorilant
For investors analyzing Corcept Therapeutics, the key questions now center on relacorilant’s commercial launch: pricing, uptake in platinum‑resistant ovarian cancer, potential label expansions, and ex‑U.S. partnerships. Strong clinical data, an oral regimen, and a high‑need ovarian cancer segment give Corcept a meaningful opportunity to drive long‑term revenue growth and support further upside in CORT stock.
